BioSpace News Archive

Rigel Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2021, including sales of TAVALISSE® tablets, for the treatment of adults with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended March 31, 2021.

Nevro Corp., a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, reported its financial results for the first quarter ended March 31, 2021 and provided updated 2021 guidance.

Cutera, Inc., a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide, announced that Jason Richey has resigned as President and Chief Operating Officer, effective May 4th, 2021, to pursue other career opportunities.

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the first quarter of 2021, and provided updates on its strong ophthalmology pipeline.

STAAR Surgical Company, a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, reported financial results for the first quarter ended April 2, 2021.

Cutera, Inc., a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide, reported financial results for the first quarter ended March 31, 2021.

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, reported financial results for the first quarter ended March 31, 2021 and provided a review of recent business and clinical highlights.

Q1 GAAP revenue including grant revenue $27.2M; Q1 non-GAAP revenue $24.9M, an increase of 58% versus prior year

Outset Medical, Inc., a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, reported financial results for the first quarter ended March 31, 2021.